ERAS on Nasdaq
Erasca, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
$15.00 up 0.30 (2.04%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $92.9M | $115.4M |
| In-process research and development | $9.5M | $22.5M |
| General and administrative | $38.6M | $41.7M |
| Total operating expenses | $140.9M | $179.6M |
| Loss from operations | -$140.9M | -$179.6M |
| Interest income | $16.6M | $20.1M |
| Other expense, net | -$248.0K | -$2.2M |
| Total other income (expense), net | $16.4M | $17.9M |
| Net loss | -$124.5M | -$161.7M |
| Net loss per share, basic | -$0.44 | -$0.69 |
| Net loss per share, diluted | -$0.44 | -$0.69 |
| Weighted-average shares of common stock used in computing net loss per share, basic | 283.5M shares | 233.8M shares |
| Weighted-average shares of common stock used in computing net loss per share, diluted | 283.5M shares | 233.8M shares |
| Unrealized gain on marketable securities, net | $223.0K | $328.0K |
| Comprehensive loss | -$124.3M | -$161.3M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $73.8M | $67.7M | |
| Short-term marketable securities | $202.3M | $230.6M | |
| Prepaid expenses and other current assets | $10.2M | $10.5M | |
| Total current assets | $286.2M | $308.8M | |
| Long-term marketable securities | $65.7M | $142.2M | |
| Property and equipment, net | $13.3M | $16.3M | |
| Operating lease assets | $29.0M | $32.2M | |
| Restricted cash | $408.0K | $408.0K | |
| Other assets | $1.5M | $2.6M | |
| Total assets | $396.2M | $502.5M | |
| Accounts payable | $981.0K | $468.0K | |
| Accrued expenses and other current liabilities | $22.5M | $26.3M | |
| Operating lease liabilities | $5.1M | $4.6M | |
| Total current liabilities | $28.5M | $31.4M | |
| Operating lease liabilities, net of current portion | $42.1M | $47.3M | |
| Other liabilities | $399.0K | $362.0K | |
| Total liabilities | $71.0M | $79.0M | |
| Preferred stock, $0.0001 par value; 80,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2025 and 2024; 284,159,076 and 283,218,344 shares issued and outstanding at December 31, 2025 and 2024, respectively | $28.0K | $28.0K | |
| Additional paid-in capital | $1.2B | $1.2B | |
| Accumulated other comprehensive income | $628.0K | $405.0K | |
| Accumulated deficit | -$892.2M | -$767.7M | |
| Total stockholders' equity | $325.2M | $423.5M | $316.7M |
| Total liabilities and stockholders' equity | $396.2M | $502.5M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 80.0M shares | 80.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 800.0M shares | 800.0M shares | |
| Common stock, shares issued | 284.2M shares | 283.2M shares | |
| Common stock, shares outstanding | 284.2M shares | 283.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $73.8M | $67.7M | |
| Short-term marketable securities | $202.3M | $230.6M | |
| Prepaid expenses and other current assets | $10.2M | $10.5M | |
| Total current assets | $286.2M | $308.8M | |
| Long-term marketable securities | $65.7M | $142.2M | |
| Property and equipment, net | $13.3M | $16.3M | |
| Operating lease assets | $29.0M | $32.2M | |
| Restricted cash | $408.0K | $408.0K | |
| Other assets | $1.5M | $2.6M | |
| Total assets | $396.2M | $502.5M | |
| Accounts payable | $981.0K | $468.0K | |
| Accrued expenses and other current liabilities | $22.5M | $26.3M | |
| Operating lease liabilities | $5.1M | $4.6M | |
| Total current liabilities | $28.5M | $31.4M | |
| Operating lease liabilities, net of current portion | $42.1M | $47.3M | |
| Other liabilities | $399.0K | $362.0K | |
| Total liabilities | $71.0M | $79.0M | |
| Preferred stock, $0.0001 par value; 80,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2025 and 2024; 284,159,076 and 283,218,344 shares issued and outstanding at December 31, 2025 and 2024, respectively | $28.0K | $28.0K | |
| Additional paid-in capital | $1.2B | $1.2B | |
| Accumulated other comprehensive income | $628.0K | $405.0K | |
| Accumulated deficit | -$892.2M | -$767.7M | |
| Total stockholders' equity | $325.2M | $423.5M | $316.7M |
| Total liabilities and stockholders' equity | $396.2M | $502.5M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 80.0M shares | 80.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 800.0M shares | 800.0M shares | |
| Common stock, shares issued | 284.2M shares | 283.2M shares | |
| Common stock, shares outstanding | 284.2M shares | 283.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$124.5M | -$161.7M |
| Depreciation and amortization | $3.1M | $3.8M |
| Stock-based compensation expense | $24.9M | $27.0M |
| In-process research and development expenses | $9.5M | $22.5M |
| Accretion on marketable securities, net | -$5.1M | -$9.6M |
| Impairment charge on operating lease assets and property and equipment | $4.7M | |
| Impairment charge on investment in equity securities | $2.2M | |
| Prepaid expenses and other current and long-term assets | $1.8M | -$2.4M |
| Accounts payable | $513.0K | -$1.5M |
| Accrued expenses and other current and long-term liabilities | -$3.8M | $6.4M |
| Operating lease assets and liabilities, net | -$1.9M | -$732.0K |
| Net cash used in operating activities | -$95.5M | -$109.4M |
| Purchases of marketable securities | -$151.0M | -$403.2M |
| Maturities of marketable securities | $261.0M | $269.3M |
| In-process research and development | -$9.5M | -$22.5M |
| Payment made for investment in equity securities | -$157.0K | |
| Purchases of property and equipment | -$128.0K | -$60.0K |
| Net cash provided by (used in) investing activities | $100.4M | -$156.6M |
| Proceeds from issuance of common stock in private placement, net of fees and expenses | $43.6M | |
| Proceeds from the exercise of stock options | $372.0K | $836.0K |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | $724.0K | $800.0K |
| Net cash provided by financing activities | $1.1M | $240.7M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $6.1M | -$25.3M |
| Vesting of early exercised options | $465.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Erasca, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerJonathan E. Lim Feb 3, 2022 to now11
- ChairJonathan E. Lim Feb 3, 2022 to now11
- PresidentCharles S. Fuchs Aug 12, 2026 to now12
- Chief financial officerDavid M. Chacko Jul 15, 2021 to now13
Board members and other officers (12)
- Chief Medical OfficerShannon Morris Apr 13, 2023 to now14
- OfficerJonathan E. Lim Jul 15, 2021 to Jul 20, 202115
- Chief Medical OfficerLin Wei Jul 15, 2021 to Feb 3, 202316
- Board memberJean I. Liu Apr 27, 2022 to now17
- Board memberAlexander W. Casdin Jul 15, 2021 to now18
- Board memberBihua Chen Jul 15, 2021 to Jun 26, 202319
- Board memberJonathan E. Lim Jul 15, 2021 to Jul 20, 202115
- Board memberJulie Hambleton Jul 15, 2021 to now20
- Board memberMichael David Varney Jul 15, 2021 to now21
- Board memberPratik S. Multani Jul 15, 2021 to now22
- Board memberValerie Denise Harding Start Jul 15, 2021 to now23
- General counselEbun Garner Jul 15, 2021 to now24
Timeline
- Feb 3, 2022New chief executive Jonathan E. Lim becomes CEO11
Filings
300 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 105 insider forms, 39 large holders, 79 other. The latest 20:
- Oct 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Aug 24, 20268-K EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20264 EDGAR
- Aug 12, 20263 EDGAR
- Aug 11, 2026S-8 EDGAR
- Aug 11, 202610-Q EDGAR
- Aug 11, 20268-K EDGAR
- Aug 10, 20268-K EDGAR
- Jul 21, 2026144 EDGAR
- Jul 14, 20268-K EDGAR
- Jul 14, 2026424B5 EDGAR
- Jul 13, 2026424B5 EDGAR
- Jul 13, 20268-K EDGAR
- Jul 13, 2026S-3ASR EDGAR
- Jul 1, 20268-K EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
The 300 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 39 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 12, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Jan 14, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | $457.5M | 10.0% | +300,000 |
| BlackRock, Inc. | 21,154,146 | $387.5M | 0.0% | +1,002,740 |
| Rtw Investments, LP | 17,946,754 | $328.8M | 2.8% | +1,789,579 |
| Venrock Adviser, LLC | 17,891,812 | $327.8M | 9.9% | +1,509,000 |
| State Street Corp | 12,184,555 | $223.2M | 0.0% | +2,884,471 |
| Logos Global Management LP | 12,150,000 | $222.6M | 9.6% | +1,000,000 |
| Vanguard Capital Management LLC | 11,402,199 | $208.9M | 0.0% | +152,461 |
| Siren, L.L.C. | 11,397,781 | $208.8M | 4.2% | +153,535 |
| Paradigm Biocapital Advisors LP | 9,550,000 | $175.0M | 3.3% | −842,702 |
| ARCH Venture Management, LLC | 7,091,557 | $129.9M | 11.8% | No change |
| Geode Capital Management, LLC | 6,501,426 | $119.1M | 0.0% | +505,277 |
| Cormorant Asset Management, LP | 6,000,000 | $109.9M | 5.6% | +200,000 |
| Affinity Asset Advisors, LLC | 5,250,000 | $96.2M | 4.8% | −100,000 |
| Vivo Capital, LLC | 4,127,412 | $75.6M | 6.9% | −8,024,068 |
| Goldman Sachs Group Inc | 3,822,113 | $70.0M | 0.0% | −1,053,073 |
| Alliancebernstein L.P. | 4,118,614 | $66.6M | 0.0% | +1,473,694 |
| Bank Of America Corp /de/ | 3,048,737 | $55.9M | 0.0% | −7,160 |
| Fmr LLC | 2,883,417 | $52.8M | 0.0% | +1,393,337 |
| a16z Capital Management, L.L.C. | 2,862,500 | $52.4M | 0.4% | No change |
| Woodline Partners LP | 2,831,867 | $51.9M | 0.2% | +329 |
| Jennison Associates LLC | 2,788,412 | $51.1M | 0.0% | New |
| Soleus Capital Management, L.P. | 2,700,000 | $49.5M | 1.7% | New |
| Vanguard Portfolio Management LLC | 2,389,864 | $43.8M | 0.0% | +616,107 |
| Samlyn Capital, LLC | 2,256,986 | $41.3M | 0.7% | New |
| Bnp Paribas Financial Markets | 2,042,034 | $37.4M | 0.0% | +954,733 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARErasca, Inc. filings on SEC EDGAR
- 2Yahoo FinanceERAS quote
- 3SEC EDGARErasca, Inc. filings on SEC EDGAR
- 4SEC EDGARErasca, Inc. 10-K for fiscal 2020
- 5SEC EDGARErasca, Inc. 10-K for fiscal 2021
- 6SEC EDGARErasca, Inc. 10-K for fiscal 2022
- 7SEC EDGARErasca, Inc. 10-K for fiscal 2023
- 8SEC EDGARErasca, Inc. 10-K for fiscal 2024
- 9SEC EDGARErasca, Inc. 10-Q for fiscal 2026
- 10SEC EDGARErasca, Inc. 10-Q for fiscal 2026
- 11
- 12SEC EDGARCharles S. Fuchs, President
- 13
- 14
- 15SEC EDGARJonathan E. Lim, Officer
- 16SEC EDGARLin Wei, Chief Medical Officer
- 17SEC EDGARJean I. Liu, Board member
- 18SEC EDGARAlexander W. Casdin, Board member
- 19SEC EDGARBihua Chen, Board member
- 20SEC EDGARJulie Hambleton, Board member
- 21SEC EDGARMichael David Varney, Board member
- 22SEC EDGARPratik S. Multani, Board member
- 23
- 24SEC EDGAREbun Garner, General counsel